A 26-week, Randomized, Double Blind, Parallel-group Multicenter Study to Assess the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Name: A 26-week, Randomized, Double Blind, Parallel-group Multicenter Study to Assess the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
Creator: Vivli
Published: 2025-12-16T15:15:25+08:00

DataCite Commons2025-12-16 更新2026-05-07 收录

COPD药物治疗

临床疗效对比

数据链接：

https://search.vivli.org/doiLanding/studies/PR00012355/isLanding 数据链接链接失效反馈

官方服务：

资源简介：

This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD

提供机构：

Vivli

创建时间：

2025-12-16